SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-21-000104
Filing Date
2021-05-07
Accepted
2021-05-07 16:05:25
Documents
15
Period of Report
2021-05-05
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20210505.htm   iXBRL 8-K 41003
2 EX-3.1 rvnccertifiedvoteresults8x.htm EX-3.1 9321
  Complete submission text file 0001479290-21-000104.txt   200882

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20210505.xsd EX-101.SCH 2458
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20210505_cal.xml EX-101.CAL 744
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20210505_def.xml EX-101.DEF 1689
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20210505_lab.xml EX-101.LAB 25282
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20210505_pre.xml EX-101.PRE 13221
8 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20210505_htm.xml XML 11768
Mailing Address 7555 GATEWAY BLVD NEWARK CA 94560
Business Address 1222 DEMONBREUN STREET SUITE 1001 NASHVILLE TN 37203 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 21902584
SIC: 2834 Pharmaceutical Preparations